Tuberculosis
- Topics
- Basic TB Facts
- Treatment
- Testing & Diagnosis
- TB & HIV Coinfection
- Infection Control & Prevention
- Drug-Resistant TB
- TB in Specific Populations
- African-American Community
- Correctional Facilities
- Table of Contents
- Introduction
- Strengthen TB Information Systems and Program Assessment
- Strengthen TB Environmental Controls and Isolation Practices
- Provide More Comprehensive and Timely Screening and Diagnostic Evaluations
- Develop and Strengthen Contact Investigation Protocols
- Increase HIV Counseling and Testing
- Increase Staff Training
- Strengthen Collaboration Between Health Departments and Jails
- International Travelers
- Pregnancy
- Disaster Responders
- Children
- Vaccines & Immunizations
- Laboratory Information
- Drug Susceptibility Testing
- The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TB
- Rapid Molecular Testing to Detect Drug-Resistant TB in the US
- Executive Summary
- Introduction
- Background on Tests for Molecular Detection of DR
- General Considerations and Principles for a Molecular DR Testing Service�
- Possible Scenarios and Scope of Testing for a Molecular DR Testing Service
- Research Needs
- General Recommendations of the Expert Panel
- Communication Plan for the Report
- Recommendations
- References
- Panel Members and CDC Participants
- Appendix 1
- Appendix 2
- Appendix 3
- Interim Laboratory Biosafety Guidance for XDR Mycobacterium tuberculosis strains
- Molecular Detection of Drug Resistance (MDDR)
- Research
- TB Epidemiologic Studies Consortium
- Background
- Infrastructure
- Research Projects
- Publications
- Meetings
- Directory
- TBESC Committee Members
- Translating Research into Practice (TRIP)
- Contact TBESC
- Prospective Evaluation of Immunogenetic and Immunologic Markers for Susceptibility to Tuberculosis Infection and Progression from M. Tuberculosisinfection to active TB
- Zero Tolerance for Pediatric TB
- Models for Incorporating HIV Counseling, Testing, and Referral into Tuberculosis Contact Investigations
- Prevalence of Latent TB Infection Among High Risk Populations in the United States
- Regional Capacity-Building in Low-Incidence Areas
- Use of Network Analysis Methods to Characterize M. tuberculosis Transmission Patterns Among Women and Other High-Risk Populations
- An Analysis of Molecular Epidemiology of Multi-Drug Resistant M. tuberculosisin the United States
- Missed Opportunities for TB Prevention in Foreign-Born Population in the United States and Canada
- New Model for Assessing TB Surveillance and Action Performance and Cost
- Addressing TB Among African Americans in the Southeast: Identifying and Overcoming Barriers to Treatment Adherence for Latent TB Infection and TB Disease
- Assessing the TB Knowledge, Attitudes, Beliefs, and Practices Among Private Providers Serving Foreign-born Populations at Risk for TB
- Factors Associated with Acceptance of, Adherence to and Toxicity From Treatment for Latent TB Infection and Pilot Study of Treatment for Latent TB Infection Effectiveness
- Culturally Appropriate TB Educational Materials for Leaders and Staff of Hispanic Service Organizations
- Enhancing TB Programs� Capacity for Self-Evaluation: Testing New Tools and Developing an Evaluation Toolkit
- African Refugee Women�s Health Improvement Project
- Evaluation of the TK Medium: A New Rapid Solid Culture System for Tuberculosis
- Evaluation of New Interferon-y Release Assays in the Diagnosis of Latent TB Infection in Health Care Workers
- Request for Proposal
- TB Trials Consortium
- Behavioral & Social Science Research
- TB Epidemiologic Studies Consortium
- Data & Statistics
- Education & Training
- Resources for TB Programs
- Publications & Products
- Fact Sheets
- General
- Fact sheets - Spanish
- TB - General Information
- The Difference Between Latent TB Infection and Active TB Disease
- Diferencia entre la infección de tuberculosis latente y enfermedad de tuberculosis activa
- A Global Perspective on TB
- Tuberculosis Information for Employers in Non-Healthcare Settings
- Bovine Tuberculosis in Humans
- Tuberculosis Information for International Travelers
- TB Can Be Treated
- Exposure to TB
- TB and HIV/AIDS
- You Can Prevent TB
- Testing for TB
- Tuberculosis: informaci�n general
- Diferencia entre la infecci�n de tuberculosis latente y enfermedad de tuberculosis activa
- Informaci�n sobre la tuberculosis para los viajeros internacionales
- Exposición a la tuberculosis
- Usted puede prevenir la tuberculosis
- La tuberculosis puede ser tratada
- Tuberculosis y VIH/SIDA
- Usted puede prevenir la tuberculosis
- Pruebas para detectar la tuberculosis
- Data & Statistics
- A Global Perspective on TB
- Trends in Tuberculosis – United States
- The Revised Report of Verified Case of Tuberculosis
- The National Tuberculosis Indicators Project (NTIP)
- National Tuberculosis Indicators Project (NTIP): Frequently Asked Questions
- TB Genotyping
- TB Genotyping Information Management System (TB GIMS)
- Drug-Resistant TB
- Multidrug-Resistant Tuberculosis (MDR TB)
- Extensively Drug-Resistant Tuberculosis (XDR TB)
- CDC’s Role in Preventing Extensively Drug-Resistant Tuberculosis (XDR TB)
- Tuberculosis multirresistente (MDR)
- Tuberculosis extremadamente resistente (XDR)
- El papel de los CDC en la prevenci�n de la tuberculosis extremadamente resistente (XDR)
- Infection Control & Prevention
- TB in Specific Populations
- Tuberculosis Information for Employers in Non-Healthcare Settings
- Tuberculosis in Minorities
- Tuberculosis Information for International Travelers
- TB and HIV/AIDS
- Recommendations for Human Immunodeficiency Virus (HIV) Screening in Tuberculosis (TB) Clinics
- Treatment of Drug-Susceptible Tuberculosis Disease in HIV-Infected Persons
- Tuberculosis in Blacks
- Tuberculosis and Pregnancy
- Tuberculosis y embarazo
- Treatment
- TB Can Be Treated
- Treatment of Latent TB Infection
- Treatment of Latent Tuberculosis Infection: Maximizing Adherence
- Treatment Options for Latent Tuberculosis Infection
- Treatment of Drug-Resistant Tuberculosis
- Treatment of Drug-Susceptible Tuberculosis Disease in Persons Not Infected with HIV
- Treatment of Drug-Susceptible Tuberculosis Disease in HIV-Infected Persons
- Tratamiento de la infecci�n de tuberculosis latente
- Testing & Diagnosis
- TB Can Be Treated
- Testing for TB
- Recommendations for Human Immunodeficiency Virus (HIV) Screening in Tuberculosis (TB) Clinics
- Interferon-Gamma Release Assays (IGRAs)
- Tuberculin Skin Testing
- Diagnosis of Tuberculosis Disease
- Targeted Tuberculin Testing and Interpreting Tuberculin Skin Test Results
- Prueba cutánea de la tuberculina
- Diagnóstico de la tuberculosis activa
- Vaccines & Immunizations
- General
- Guidelines
- Guides & Toolkits
- Core Curriculum
- Self-Study Modules
- Report of Verified Case of Tuberculosis (RVCT)
- Forging Partnerships to Eliminate TB
- Understanding the TB Cohort Review Process
- Latent Tuberculosis Infection: A Guide for Primary Health Care Providers
- Effective TB Interviewing for Contact Investigation
- Mantoux Tuberculin Skin Testing Products
- Ethnographic Guides
- Newsletters
- Pamphlets, Brochures, Booklets
- Posters
- Mantoux Tuberculin Skin Test Wall Chart
- World TB Day
- Afiches
- 2011 Poster (English)
- 2011 Poster (Spanish)
- 2010 Poster (English)
- 2010 Poster (Spanish)
- 2008 Poster (English)
- 2008 Poster (Spanish)
- 2006 Poster (English)
- 2004 Poster (English)
- 2004 Poster (Spanish)
- 2003 Poster (English)
- 2003 Poster (Spanish)
- 2003 Now is the Time Poster (English)
- 2003 Now is the Time Poster (Spanish)
- Think TB
- Stop TB
- Reports & Articles
- Morbidity and Mortality Weekly Reports (MMWRs)
- Contact Investigations
- Control and Elimination
- Data & Statistics
- Drug-Resistant Tuberculosis
- Infection Control & Prevention
- Laboratory
- TB in Specific Populations
- Foreign-Born
- High-Risk Settings
- Homeless
- International
- Occupational Groups
- Travel
- TB & HIV
- Testing & Diagnosis
- Treatment
- LTBI Updates
- Vaccines & Immunizations
- World TB Day
- DTBE Authored Journal Articles
- Tuberculosis Laboratory Aggregate Reports
- Morbidity and Mortality Weekly Reports (MMWRs)
- Slide Sets
- Core Curriculum
- Self-Study Modules
- Prevention and Control of Tuberculosis in Correctional and Detention Facilities
- Guidelines for Preventing the Transmission of M. TB in Health care Settings
- Investigation of Contacts of Persons with Infectious TB
- Text-Only version
- Introduction
- Decisions to Initiate a Contact Investigation
- Investigating the Index Patient and Sites of Transmission
- Assigning Priorities to Contacts
- Diagnostic and Public Health Evaluation of Contacts
- Medical Treatment for Contacts with LTBI
- When to Expand a Contact Investigation
- Communicating Through the News Media
- Data Management and Evaluation of Contact Investigations
- Confidentiality and Consent in Contact Investigations
- Staff Training for Contact Investigations
- Contact Investigations in Special Circumstances
- Source-Case Investigations
- Cultural Competency and Social Network Analysis
- Resources
- Epidemiology of Pediatric Tuberculosis in the United States
- Text-Only version
- Introduction
- Pediatric TB Cases by Age and Race
- Pediatric TB Cases by Origin of Birth
- Pediatric Cases, Percentages and Rates by States
- Pediatric TB Cases by Case Verification Criterion and Site of Disease
- Pediatric TB Cases in Specific Groups
- Pediatric TB Cases Case Completion
- Slide 1
- Slide 2
- Slide 3
- Slide 4
- Slide 5
- Slide 6
- Slide 7
- Slide 8
- Slide 9
- Slide 10
- Slide 11
- Slide 12
- Slide 13
- Slide 14
- Slide 15
- Slide 16
- Slide 17
- Slide 18
- Slide 19
- Slide 20
- Slide 21
- Slide 22
- Slide 23
- Slide 24
- Slide 25
- Slide 26
- Slide 27
- Slide 28
- Slide 29
- Slide 30
- Slide 31
- Treatment of TB
- Targeted Tuberculosis Testing and Treatment of Latent Tuberculosis Infection
- CD Roms
- Electronic Tools & Resources
- Web-Based Courses & Webinars
- Fact Sheets
- Global TB
- Events
- Links
- About Us
- Mission Statement and Activities
- Organization Chart
- Advisory Groups
- Federal TB Task Force
- Table of Contents
- Executive Summary
- Introduction
- Chronology in the Development of This Report
- Strategies for Maintaining Control of TB
- Strategies for Accelerating the Decline of TB
- Activities for Developing New Tools
- Global U.S. Actions
- Assessing the Impact of Actions Taken
- Federal TB Task Force Members and Others Involved in the Development of This Report
- Glossary
- References
- Federal TB Task Force Roster
- Table of Contents
- Executive Summary
- Introduction
- How to Eliminate TB? – The IOM Report
- Why Eliminate TB? – Rationale for Elimination
- Who Will Lead? – CDC's Response
- Goal I: Maintain control of TB
- Goal II: Accelerate the decline
- Goal III: Create new tools
- Goal IV: Reduce the global burden of TB
- Goal V: Summon and sustain support
- Goal VI: Track progress
- References
- Federal TB Task Force
- Funding
Reported Tuberculosis in the United States, 2010
Surveillance Report
- Full Report (PDF – 3MB)
- Preface (PDF – 558k)
- Executive Commentary (PDF – 270k)
- Technical Notes (PDF – 351k)
NOTE: Click the links below to show or hide the tables for each section.
Morbidity Trend Tables, United States
- Table 1. Tuberculosis Cases, Case Rates per 100,000 Population, Deaths, and Death Rates per 100,000 Population, and Percent Change: United States, 1953–2010 (PDF - 262k)
- Table 2. Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Hispanic Ethnicity and non-Hispanic Race: United States, 1993–2010 (PDF - 276k)
- Table 3. Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Race Only: United States, 1993–2010 (PDF - 273k)
- Table 4. Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Age Group: United States, 1993–2010 (PDF - 278k)
- Table 5. Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Origin of Birth: United States, 1993–2010 (PDF - 275k)
- Table 6. Tuberculosis Cases and Percentages Among Foreign-born Persons by the Top 30 Countries of Origin of Birth: United States, 2005–2010 (PDF - 253k)
- Table 7. Tuberculosis Cases and Percentages Among Adult Foreign-born Persons by Country of Origin and Years in the United States Before TB Diagnosis, Top 30 Countries: United States, 2010 and 2000 (PDF - 283k)
- Table 8. Tuberculosis Cases and Percentages by Case Verification Criterion and Site of Disease: United States, 1993–2010 (PDF - 312k)
- Table 9. Pulmonary Tuberculosis Cases and Percentages by Sputum Smear and Sputum Culture Results: United States, 1993–2010 (PDF - 308k)
- Table 10. Tuberculosis Cases and Percentages, by Resistance to INH or Multidrug Resistance in Persons with No Previous History of TB, by Origin of Birth: United States, 1993–2010 (PDF - 263k)
- Table 11. Tuberculosis Cases and Percentages, by Resistance to INH or Multidrug Resistance in Persons with Previous History of TB, by Origin of Birth: United States, 1993–2010 (PDF - 260k)
- Table 12. Percentages of Tuberculosis Cases by Initial Drug Regimen, Use of Directly Observed Therapy (DOT), and Completion of Therapy (COT): United States, 1993–2010 (PDF - 254k)
- Table 13. Tuberculosis Cases and Percentages in Persons with HIV Test Results and with HIV Coinfection, by Age Group: United States, 1993–2010 (PDF - 251k)
- Table 14. Tuberculosis Cases and Percentages by Reason Tuberculosis Therapy Stopped: United States, 1993–2008 (PDF - 249k)
Morbidity Tables, United States, 2010
- Table 15. Tuberculosis Cases by Hispanic Ethnicity and Non-Hispanic Race, Sex, and Age Group: United States, 2010 (PDF - 266k)
- Table 16. Tuberculosis Case Rates per 100,000 Population by Hispanic Ethnicity and Non-Hispanic Race, Sex, and Age Group: United States, 2010 (PDF - 260k)
- Table 17. Tuberculosis Cases in U.S.-born Persons by Hispanic Ethnicity and Non-Hispanic Race, Sex, and Age Group: United States, 2010 (PDF - 252k)
- Table 18. Tuberculosis Cases in Foreign-born Persons by Hispanic Ethnicity and Non-Hispanic Race, Sex, and Age Group: United States, 2010 (PDF - 266k)
- Table 19. Tuberculosis Cases by Country of Origin: United States, 2010 (PDF - 389k)
Morbidity Tables Reporting Areas, 2010
- Table 20. Tuberculosis Cases and Case Rates per 100,000 Population: Reporting Areas, 2010 and 2009 (PDF - 274k)
- Table 21. Tuberculosis Cases and Percentages by Age Group: Reporting Areas, 2010 (PDF - 454k)
- Table 22. Tuberculosis Cases and Percentages by Hispanic Ethnicity and Non-Hispanic Race: Reporting Areas, 2010 (PDF - 471k)
- Table 23. Tuberculosis Cases and Percentages, U.S.-born and Foreign-born Persons: States, 2010 (PDF - 256k)
- Table 24. Tuberculosis Cases and Percentages in Foreign-born Persons by Country of Origin: States, 2010 (PDF - 395k)
- Table 25. Tuberculosis Cases and Percentages in Foreign-born Persons by Number of Years in the United States: States, 2010 (PDF - 286k)
- Table 26. Tuberculosis Cases and Percentages by Pulmonary and Extrapulmonary Disease: Reporting Areas, 2010 (PDF - 278k)
- Table 27. Extrapulmonary Tuberculosis Cases and Percentages by Site of Disease: Reporting Areas, 2010 (PDF - 461k)
- Table 28. Tuberculosis Cases and Case Rates per 100,000 Population, Ranked and Grouped by Number of Cases: States and the District of Columbia, 2010 and 2009 (PDF - 270k)
Morbidity Tables, Reporting Areas, 2010 and 2008
- Table 29. Tuberculosis Cases and Percentages by Residence in Correctional Facilities, Age ≥15: Reporting Areas, 2010 (PDF - 255k)
- Table 30. Tuberculosis Cases and Percentages by Homeless Status, Age ≥15: Reporting Areas, 2010 (PDF - 255k)
- Table 31. Tuberculosis Cases and Percentages by Residence in Long-term Care Facilities, Age ≥15: Reporting Areas, 2010 (PDF - 255k)
- Table 32. Tuberculosis Cases and Percentages by Injecting Drug Use, Age ≥15: Reporting Areas, 2010 (PDF - 268k)
- Table 33. Tuberculosis Cases and Percentages by Noninjecting Drug Use, Age ≥15: Reporting Areas, 2010 (PDF - 269k)
- Table 34. Tuberculosis Cases and Percentages by Excess Alcohol Use, Age ≥15: Reporting Areas, 2010 (PDF - 269k)
- Table 35. Tuberculosis Cases and Percentages by Initial Drug Regimen: Reporting Areas, 2010 (PDF - 261k)
- Table 36. Culture-Positive Tuberculosis Cases and Percentages with Drug Susceptibility Results, by Resistance to INH or Multidrug Resistance: Reporting Areas, 2010 (PDF - 275k)
- Table 37. Tuberculosis Cases and Percentages Among Persons Aged 25–44 by HIV Status: Reporting Areas, 2010 (PDF - 269k)
- Table 38. Tuberculosis Cases and Percentages by Primary Occupation, Age ≥15: Reporting Areas, 2010 (PDF - 284k)
- Table 39. Tuberculosis Cases and Percentages by Type of Health Care Provider: Reporting Areas, 2008 (PDF - 275k)
- Table 40. Tuberculosis Cases and Percentages by Directly Observed Therapy (DOT): Reporting Areas, 2008 (PDF - 273k)
- Table 41. Tuberculosis Cases and Percentages by Completion of Tuberculosis Therapy (COT): Reporting Areas, 2008 (PDF - 279k)
- Table 42. Tuberculosis Cases and Percentages by Reason Therapy Stopped: Reporting Areas, 2008 (PDF - 402k)
- Table 43. Completion of Tuberculosis Therapy (COT) Cases and Percentages by Hispanic Ethnicity and Non-Hispanic Race: Reporting Areas, 2008 (PDF - 424k)
- Table 44. Tuberculosis Cases and Percentages in Persons Completing Therapy for Whom Therapy Was Indicated for One Year or Less: Reporting Areas, 2004–2008 (PDF - 285k)
Morbidity Tables, Cities and Metropolitan Statistical Areas, 2010
- Table 45. Tuberculosis Cases in Selected Cities: 2010 and 2009 (PDF- 259k)
- Table 46. Tuberculosis Cases and Case Rates per 100,000 Population: Metropolitan Statistical Areas with ≥ 500,000 Population, 2010 and 2009 (PDF - 353k)
- Table 47. Tuberculosis Cases by Pulmonary and Extrapulmonary Disease: Metropolitan Statistical Areas with ≥ 500,000 Population, 2010 (PDF - 396k)
- Table 48. Tuberculosis Cases by Age Group: Metropolitan Statistical Areas with ≥ 500,000 Population, 2010 (PDF - 394k)
- Table 49. Tuberculosis Cases by Hispanic Ethnicity and Non-Hispanic Race: Metropolitan Statistical Areas with ≥ 500,000 Population, 2010 (PDF - 406k)
- Table 50. Tuberculosis Cases and Percentages, U.S.-born Persons and Foreign-born Persons: Metropolitan Statistical Areas with >500,000 Population, 2010 (PDF - 382k)
Appendices
- United States Affiliated Pacific Islands, 2010 (PDF - 677k)
- Appendix A: Tuberculosis Case Definition for Public Health Surveillance (PDF - 360k)
- Appendix B: Recommendations for Counting Reported Tuberculosis Cases (PDF - 472k)
- Appendix C: National Surveillance for Severe Adverse Events Associated with Treatment for Latent Tuberculosis Infection - Reporting Information (PDF - 326k)
Surveillance Slide Set, 2010
- Surveillance Slide Set, 2010 (PPT - 764K)
- Slides
- Slide Narratives (PDF – 37k)
Suggested Citation: CDC. Reported Tuberculosis in the United States, 2010. Atlanta, GA: U.S. Department of Health and Human Services, CDC, October 2011.
Related Links
Contact Us:
- Centers for Disease Control and Prevention
Division of Tuberculosis Elimination (DTBE)
1600 Clifton Rd., NE
MS E10
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348 - New Hours of Operation
8am-8pm ET/Monday-Friday
Closed Holidays - cdcinfo@cdc.gov
